NKGEN BIOTECH INC (NKGN)
US65488A1016 - Common Stock
NKGen Biotech Selected as Stalking Horse Bidder for NKMax
NKGen Biotech Selected as Stalking Horse Bidder for NKMax
Upon closing, the transaction would secure global IP rights for NKGen.NKGen and its partners can begin to commercialize troculeucel in Korea, Japan and...
NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel
NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel
SANTA ANA, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), today announced it received a notice...
NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Newly analyzed biomarker data from the initial dose-escalation Phase 1 AD trial found that troculeucel reduces GFAP, NfL, p-tau181, GDF-15, and LTBP2...
NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024)
NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024)
SANTA ANA, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company...
NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
SANTA ANA, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company...
NKGen Biotech’s Positive Phase 1 Clinical Data in Moderate Alzheimer’s Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial
Two of the first three patients in the Phase 1 cohort of the Phase 1/2a clinical trial, treated at the highest dose of 6 billion cells per treatment, were...
NKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference
NKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference
SANTA ANA, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology...
NKGen Biotech Receives Notification From Nasdaq Related to Delayed Quarterly Report
NKGen Biotech Receives Notification From Nasdaq Related to Delayed Quarterly Report
SANTA ANA, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), today announced it received a...
NKGen Biotech Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer’s Association International Conference
SNK01, a cryopreserved autologous non-genetically modified NK cell product, is able to effectively reduce α-synuclein (α-syn) protein levels in the...
Barclays Just Raised Its Price Target on Intuitive Surgical (ISRG) Stock
Intuitive Surgical stock is falling on Thursday even after shares of ISRG got an increased price target from Barclays analysts.
WBD Stock Pops as Warner Bros. Considers Streaming Spinoff
Warner Bros. stock is rising on Thursday as reports about a potential spinoff of its streaming division embolden WBD investors.
Why Is NKGen Biotech (NKGN) Stock Up 18% Today?
NKGen Biotech stock is up Thursday as NKGN holders react to plans for a presentation at the Alzheimer’s Association International Conference.
NKGen Biotech to Present New Positive SNK01 Clinical Trial Biomarker Data at the 2024 Alzheimer’s Association International Conference
SANTA ANA, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology...
NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors
NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors
SANTA ANA, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology...
NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
SANTA ANA, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology...